Neprilysin inhibitors

US9783507B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9783507-B2
Application numberUS-201715419217-A
CountryUS
Kind codeB2
Filing dateJan 30, 2017
Priority dateJan 30, 2014
Publication dateOct 10, 2017
Grant dateOct 10, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

In one aspect, the invention relates to compounds having the formula I: where R 1 -R 6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound of Formula 1: where: R 1 is H, —C 1-8 alkyl, —CH(CH 3 )OC(O)—O-cyclohexyl, —(CH 2 ) 2 -morpholinyl, or —CH 2 - 5-methyl-[1,3]dioxol-2-one; R 2 is —C 0-3 alkylene-NR 22 R 23 ; R 22 is H or —C 1-6 alkyl; R 23 is H, —C 1-6 alkyl, —C 1-6 alkyl substituted with 1 to 6 fluoro atoms, —SO 2 —C 1-6 alkyl, —CH 2 OC(O)—C 1-6 alkyl, —C 2-4 alkylene-OH, —C 2-4 alkylene-O—CH 3 , or cyclopropyl optionally substituted with one or two R 31 groups; or R 22 and R 23 are taken together to form —(CH 2 ) 2 —O—(CH 2 ) 2 —, a 2-oxa-6-aza-spiro[3.3]heptane ring, or an azetidine ring optionally substituted with one or two R 31 groups; and each R 31 is independently halo, —C 1-6 alkyl, —C 0-2 alkylene-OH, —C 0-2 alkylene-OC 1-6 alkyl, —CN, or —CONH 2 ; R 3 , R 4 and R 5 are independently H or halo; and P 1 is H or an amino-protecting group selected from the group consisting of t-butoxycarbonyl, trityl, benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl, formyl, trimethylsilyl, and t-butyldimethylsilyl; or a salt thereof.

Assignees

Inventors

Classifications

  • with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms · CPC title

  • attached in position 2 · CPC title

  • Amides; Imides · CPC title

  • One oxygen atom attached in position 3 or 5 · CPC title

  • C07D249/04Primary

    1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9783507B2 cover?
In one aspect, the invention relates to compounds having the formula I: where R 1 -R 6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and process…
Who is the assignee on this patent?
Theravance Biopharma R&D Ip Llc
What technology area does this patent fall under?
Primary CPC classification C07D249/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Oct 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).